Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An announcement from Immutep Ltd ( (AU:IMM) ) is now available.
Immutep Limited has completed patient enrolment for its INSIGHT-003 trial, which evaluates the combination of eftilagimod alpha, pembrolizumab, and chemotherapy as a first-line treatment for advanced non-small cell lung cancer. Initial results show promising survival outcomes, with ongoing data updates expected to enhance the understanding of the treatment’s efficacy and safety in this patient group.
More about Immutep Ltd
Immutep Limited is a clinical-stage biotechnology company focusing on the development of novel LAG-3 immunotherapies for cancer and autoimmune diseases. The company is a pioneer in Lymphocyte Activation Gene-3 (LAG-3) related therapeutics, and its diverse product portfolio aims to modulate the immune response for innovative treatment options.
YTD Price Performance: 3.18%
Average Trading Volume: 1,750
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $325.8M
See more data about IMM stock on TipRanks’ Stock Analysis page.
